Stockscreener 앱 받기
6.25
4.34%
0.26
전일 마감가:
$5.99
열려 있는:
$5.99
하루 거래량:
543.91K
Relative Volume:
3.08
시가총액:
$353.88M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-4.6642
EPS:
-1.34
순현금흐름:
$-58.82M
1주 성능:
+11.61%
1개월 성능:
+14.05%
6개월 성능:
+88.82%
1년 성능:
+143.19%
1일 변동 폭
$5.86
$6.38
1주일 범위
$5.55
$6.45
52주 변동 폭
$2.245
$7.77
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
6.25 | 353.88M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
(DSGN) Investment Analysis - Stock Traders Daily
Design Therapeutics director Prasad Deepa sells shares worth $23,863 By Investing.com - Investing.com South Africa
Insider Selling: Design Therapeutics, Inc. (NASDAQ:DSGN) Director Sells 3,806 Shares of Stock - MarketBeat
Design Therapeutics director Prasad Deepa sells shares worth $23,863 - Investing.com
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
The Manufacturers Life Insurance Company Purchases Shares of 13,221 Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Design Therapeutics' SWOT analysis: geneTAC stock faces early-stage hurdles - Investing.com
Fmr LLC Has $4.46 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
Design Therapeutics Gains 11%, Insider Trades Reap Benefit - Simply Wall St
Design Therapeutics, Inc. (NASDAQ:DSGN) Position Boosted by Frazier Life Sciences Management L.P. - MarketBeat
Long Term Trading Analysis for (DSGN) - Stock Traders Daily
Orion Corporation Enters Collaboration With Evariste to Design Inhibitors of an Undisclosed Target - Yahoo Finance
Jacobs Levy Equity Management Inc. Reduces Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Acquired by Point72 Asset Management L.P. - MarketBeat
Design Therapeutics' SWOT analysis: geneTAC stock faces long road to value - Investing.com India
Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025 - Yahoo Finance
AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M - BioSpace
Cartesian Therapeutics Announces Positive Updated Results - GlobeNewswire
Applied Therapeutics Crashes After FDA Rejection of Rare Disease Drug - BioSpace
True Wealth Design LLC Reduces Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - Business Wire
Rakovina Therapeutics to present AI-driven brain cancer research at Neuro-Oncology Conference - Proactive Investors USA
(DSGN) Technical Data - Stock Traders Daily
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - The Manila Times
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - The Manila Times
Design Therapeutics (DSGN) to Present at Two Major Healthcare Conferences | DSGN Stock News - StockTitan
Design Therapeutics stock soars to 52-week high of $6.91 By Investing.com - Investing.com Canada
Design Therapeutics stock soars to 52-week high of $6.91 - Investing.com India
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies - Nature.com
PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online
Design Therapeutics Reports Strong Q3 and Pipeline Progress - TipRanks
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio - Marketscreener.com
Design Therapeutics Reports $254M Cash Runway, Advances Clinical Pipeline Through 2029 | DSGN Stock News - StockTitan
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely - Yahoo Finance
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, - GlobeNewswire
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI - Yahoo Finance
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - PR Newswire
A new biotech, built around protein design, springs from David Baker’s lab - BioPharma Dive
Dr. Beyza Bulutoglu Celebrated for Dedication to the Field of Protein Engineering and Drug Discovery - 24-7 Press Release
At-home wearable-based monitoring predicts clinical measures and biological biomarkers of disease severity in Friedreich’s Ataxia | Communications Medicine - Nature.com
Spinocerebellar Ataxias Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Seaport Therapeutics Secures $225M for New Kind of Depression Drug - MedCity News
Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases - BioSpace
Nitric Oxide-Photodelivering Materials with Multiple Functionalities: From Rational Design to Therapeutic Applications - ACS Publications
Synthetic Nanoassemblies for Regulating Organelles: From Molecular Design to Precision Therapeutics - ACS Publications
Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc - Barchart
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
디자인 테라 주식 (DSGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| William Arsani | Director |
Aug 09 '24 |
Sale |
4.25 |
814,874 |
3,463,214 |
0 |
2.88%
2.65%
자본화:
|
볼륨(24시간):